Monday market watch

Affymetrix (AFFX) was down $12.75 to $118.875 on Monday following last Friday's ruling by the English High Court that AFFX does not have a license to DNA microarray patents belonging to Oxford Gene Technology (Oxford, U.K.). The decision removes one of AFFX's defenses in a patent infringement lawsuit brought by Oxford Gene in 1999 (see BioCentury, the Bernstein Report on BioBusiness, April 10). Also on the genomics downside, Celera (CRA) was off $30.375 (23 percent) to $100 on Monday. CRA was up 42 percent last week to $130.375 on news that it had completed the genome of a single person. ...